<- Go Home
Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Market Cap
$757.9M
Volume
11.3M
Cash and Equivalents
$83.7M
EBITDA
-$133.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$9.4M
Profit Margin
8.06%
52 Week High
$5.34
52 Week Low
$1.17
Dividend
N/A
Price / Book Value
2.83
Price / Earnings
-5.66
Price / Tangible Book Value
2.83
Enterprise Value
$424.0M
Enterprise Value / EBITDA
-3.20
Operating Income
-$134.3M
Return on Equity
45.35%
Return on Assets
-16.07
Cash and Short Term Investments
$396.9M
Debt
$121.8M
Equity
$268.2M
Revenue
$116.3M
Unlevered FCF
-$127.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium